ANDA 60634, held by Purepac Pharmaceutical. Oxytetracycline Hydrochloride.
As of Nov 21, 2026, ANDA 60634 (Oxytetracycline Hydrochloride), held by Purepac Pharmaceutical, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxytetracycline HydrochlorideEQ 250MG BASE · capsule;oral | Oxytetracycline Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters